Sirnaomics is a biopharmaceutical company developing therapeutics for critical human diseases by using RNA interference technology.
Sirnaomics is a clinical-stage biopharmaceutical company developing therapeutics for critical human diseases by using RNA interference (RNAi) technology.The RNAi technology is used to discover and develop novel therapeutics with a focus on oncology, anti-fibrotic therapeutics, and viral infection. Its proprietary Polypeptide Nano-Particle (PNP) technology is used for small interfering RNA (siRNA) drug delivery. This technology allows accessing the tumor micro-environment (TME), as well as various cell types in the liver.Sirnaomics was founded by Patrick Y. Lu and David M. Evans in 2007 and is based in Gaithersburg, Maryland.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Jul 1, 2021 | Series E | $105M | 2 | Rotating Boulder Fund | — | Detail |
Oct 23, 2020 | Series D | $105M | 7 | River Head Capital Rotating Boulder Fund Walvax Biotechnology | — | Detail |
Apr 29, 2019 | Series C | $22M | 4 | CR-CP Life Science Fund | — | Detail |
Jun 6, 2018 | Series C | $25M | 4 | Guangzhou Yuexiu Industrial Investment Fund | — | Detail |
Apr 28, 2016 | Series B | $10M | 1 | Value Measured Investment Limited | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Rotating Boulder Fund | Yes | Series E |
River Head Capital | Yes | Series D |
Walvax Biotechnology | Yes | Series D |
CR-CP Life Science Fund | Yes | Series C |
Guangzhou Yuexiu Industrial Investment Fund | Yes | Series C |
Value Measured Investment Limited | Yes | Series B |
Founder H Fund | — | Series E |
Alpha Win Capital | — | Series D |
Hongtao Capital | — | Series D |
Longmen Capital | — | Series D |